drugset / Trial / NCT04835883
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
Phase 2
Unknown
10 enrolled
Hanyang University Seoul Hospital
Corestemchemon, Inc. · collabMinistry of Health & Welfare, Korea · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, one-arm single-center phase Ⅱa study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus patients - lupus nephritis and lupus cytopenia.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2021-11-05
- Completion
- 2026-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS20AT04 | Cell therapy | 2e+06 cells/kg | Intravenous |